Cardiometabolic Disorders News

Small HDL particles play a significant role in the prevention of Alzheimer’s disease, and an inherited gene present in one in four people hinders its production in the brain, increasing risk for cognitive decline, a speaker reported.

Esperion announced the FDA granted an updated indication for bempedoic acid and bempedoic acid plus ezetimibe for the treatment of primary hyperlipidemia in eligible patients with genetic hyperlipidemia or atherosclerotic CVD.

The development of incretin-based molecules has led to therapies that can induce greater reductions in HbA1c and body weight for people with type 2 diabetes and obesity than other classes of medication, according to a speaker

Composite CVD risk factor control for U.S. adults with type 2 diabetes remains poor, but clinicians can use newer risk scores to better assess patients and prevent CV events with targeted therapies, according to a speaker.

A speaker reported that improved differentiation of resistant vs. refractory hypertension is essential in choosing optimal antihypertensive treatment, as the two represent different disease states of elevated blood pressure.

Medications that target bile acid-triggered pathways and combination therapies could be the key for treating nonalcoholic steatohepatitis for young people with obesity and type 2 diabetes, according to a speaker.

Women with a history of infertility who use assisted reproductive technologies may have increased risk for CVDs, such as preeclampsia, stroke and heart failure, according to a presenter.

New guidance on obesity management and cardiovascular disease screening for people with diabetes are among the updates in the American Diabetes Association’s 2024 Standards of Care.

Global CV mortality and the prevalence of important cardiometabolic risk factors increased through 2022, with high BP remaining the strongest contributor, according to the 2023 update to the Global Burden of Disease special report on CVD.

PHILADELPHIA — Adults with obesity and atrial fibrillation treated with liraglutide plus risk factor modification had improved outcomes after catheter ablation compared with those prescribed risk factor modification alone.